FR2753097A1 - Solid dosage form giving controlled viscosity solution or dispersion - Google Patents
Solid dosage form giving controlled viscosity solution or dispersion Download PDFInfo
- Publication number
- FR2753097A1 FR2753097A1 FR9611061A FR9611061A FR2753097A1 FR 2753097 A1 FR2753097 A1 FR 2753097A1 FR 9611061 A FR9611061 A FR 9611061A FR 9611061 A FR9611061 A FR 9611061A FR 2753097 A1 FR2753097 A1 FR 2753097A1
- Authority
- FR
- France
- Prior art keywords
- dosage form
- solid dosage
- form according
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006185 dispersion Substances 0.000 title claims abstract description 26
- 239000007909 solid dosage form Substances 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000007787 solid Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000000499 gel Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 11
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 11
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 235000011837 pasties Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003349 gelling agent Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 208000005946 Xerostomia Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 238000004062 sedimentation Methods 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 239000001361 adipic acid Substances 0.000 claims description 2
- 235000011037 adipic acid Nutrition 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 claims description 2
- 229920003086 cellulose ether Polymers 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 238000010668 complexation reaction Methods 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- HDFXRQJQZBPDLF-UHFFFAOYSA-L disodium hydrogen carbonate Chemical compound [Na+].[Na+].OC([O-])=O.OC([O-])=O HDFXRQJQZBPDLF-UHFFFAOYSA-L 0.000 claims description 2
- 206010013781 dry mouth Diseases 0.000 claims description 2
- 239000001530 fumaric acid Substances 0.000 claims description 2
- 235000011087 fumaric acid Nutrition 0.000 claims description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 3
- NZZLTKHBCHMMOJ-UHFFFAOYSA-N 2-acetyloxybenzoic acid;urea Chemical compound NC(N)=O.CC(=O)OC1=CC=CC=C1C(O)=O NZZLTKHBCHMMOJ-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 12
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000000378 dietary effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 230000007547 defect Effects 0.000 description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 4
- 239000003513 alkali Substances 0.000 description 3
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000007968 orange flavor Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001915 hexamidine Drugs 0.000 description 2
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VARKFMHUVKZOHE-UHFFFAOYSA-N 2-(butan-2-ylamino)-2-oxoacetic acid Chemical compound CCC(C)NC(=O)C(O)=O VARKFMHUVKZOHE-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004105 carbasalate calcium Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
L'invention concerne le principe et la préparation de formes extemporanées et à viscosité contrôlée, dans les domaines de la pharmacie, de la cosmétologie, de l'hygiène et de la diététique. The invention relates to the principle and the preparation of extemporaneous and viscosity controlled forms, in the fields of pharmacy, cosmetology, hygiene and dietetics.
Depuis un certain nombre d'années les techniques de fabrication et de conservation des produits pharmaceutiques et parapharmaceutiques ont sans cesse permis de reculer les "dates de péremption" et de "limite d'utilisation". Mais les incompatibilités chimiques, la présence d'un solvant ou les conditionnements de certaines formes peuvent réduire les périodes de conservation: notamment les formes sèches ont toujours des délais de conservation plus élevés que les formes liquides ou pâteuses, ces dernières présentant souvent des caractéristiques physico-chimiques favorisant la contamination, la dessiccation ou la précipitation des produits solubilisés (évaporation ou fuite du solvant, réaction des produits entre eux...). For a certain number of years, the manufacturing and preservation techniques of pharmaceutical and parapharmaceutical products have constantly made it possible to postpone the "expiration dates" and "usage limits". But chemical incompatibilities, the presence of a solvent or the conditioning of certain forms can reduce the periods of conservation: in particular the dry forms always have longer periods of conservation than the liquid or pasty forms, the latter often having physical characteristics. -chemicals favoring the contamination, the desiccation or the precipitation of the solubilized products (evaporation or leakage of the solvent, reaction of the products with each other ...).
Afin d'éviter ces défauts de conservation il est souhaitable de n'incorporer le solvant qu'au moment de l'utilisation du produit par le patient ou le client. Mais s'il est aisé de dissoudre des poudres ou des mélanges effervescents à principes actifs solubles dans un volume d'eau déterminé, cette opération devient malaisée lorsque l'on désire préparer des dispersions à principes actifs insolubles, des solutions ou des dispersions visqueuses comme les gels. In order to avoid these storage defects, it is desirable to incorporate the solvent only when the product is used by the patient or the client. But if it is easy to dissolve powders or effervescent mixtures with soluble active ingredients in a given volume of water, this operation becomes difficult when it is desired to prepare dispersions with insoluble active ingredients, solutions or viscous dispersions such as gels.
Les gels ont toujours eu grâce à leur caractéristiques physico-chimiques de nombreux avantages: ils permettent de bloquer les phénomènes de sédimentation ou de précipitation de certains solutés ou dispersions, ils adhèrent pour la plupart aisément sur leur substrat (les muqueuses ou la peau) et peuvent améliorer les caractères organoleptiques de certains composants. Thanks to their physicochemical characteristics, gels have always had many advantages: they make it possible to block the phenomena of sedimentation or precipitation of certain solutes or dispersions, they mostly adhere easily to their substrate (the mucous membranes or the skin) and can improve the organoleptic characteristics of certain components.
Or les techniques de fabrication des gels sont parfaitement connues de leur fabricant: elles utilisent des agents gélifiants que l'on incorpore, sous forte agitation, au sein de solutions ou de dispersions préalablement préparées. Mais l'utilisateur final ne peut disposer d'un matériel efficace, donc complexe et encombrant, (mélangeur, homogénéisateur...) pour reproduire correctement et rapidement ces techniques. However, the techniques for manufacturing gels are perfectly known to their manufacturer: they use gelling agents which are incorporated, with vigorous stirring, into solutions or dispersions previously prepared. But the end user cannot have efficient, therefore complex and bulky equipment (mixer, homogenizer, etc.) to reproduce these techniques correctly and quickly.
Les conditionnements des gels sont généralement complexes et coûteux (flacons, tubes en polyéthylène...) et engendrent souvent des difficultés d'utilisation (casse, fuites, débordements, utilisation de contenant de transfert comme cuillères et autres doses...) D'autre part ces préparations intègrent d'origine leur solvant, ce qui grève d'autant les frais de manipulation et de transport du produit. The packaging of the gels is generally complex and costly (bottles, polyethylene tubes, etc.) and often gives rise to difficulties of use (breakage, leaks, overflows, use of transfer container like spoons and other doses, etc.). on the other hand, these preparations incorporate their solvent from their origin, which increases the costs of handling and transporting the product.
Un premier objet de la présente invention est de proposer une forme d'administration solide et sèche qui supprime ou atténue les inconvénients de celles existant dans l'état de la technique. Plus précisément, elle permet à l'utilisateur final de préparer facilement des gels à viscosité contrôlée, sans mousse, à partir de formes sèches à disperser dans un volume d'eau ou de liquide hydroalcoolique déterminé, pour un usage interne ou externe (par voie orale, sur les muqueuses ou sur la peau). A first object of the present invention is to provide a solid and dry form of administration which eliminates or mitigates the drawbacks of those existing in the prior art. More specifically, it allows the end user to easily prepare gels with controlled viscosity, without foam, from dry forms to be dispersed in a given volume of water or hydroalcoholic liquid, for internal or external use (by oral, on the mucous membranes or on the skin).
L'obtention de ces gels ne nécessite aucun appareillage technique et se réalise en quelques minutes.Obtaining these gels does not require any technical equipment and is carried out in a few minutes.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée qui permet d'obtenir rapidement et simplement des solutions ou dispersions de composés faiblement solubles ou insolubles. Another object of the present invention is to provide a form of extemporaneous administration which enables solutions and dispersions of poorly soluble or insoluble compounds to be obtained quickly and simply.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée qui permet de ralentir ou annuler les phénomènes de sédimentation, précipitation, cristallisation ou complexation de certaines solutions ou dispersions. Another object of the present invention is to provide a form of extemporaneous administration which makes it possible to slow down or cancel the phenomena of sedimentation, precipitation, crystallization or complexation of certain solutions or dispersions.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée qui permet d'obtenir rapidement et simplement des dispersions, solutions ou gels instables ou à durée de vie limitée. Another object of the present invention is to provide a form of extemporaneous administration which makes it possible to quickly and simply obtain dispersions, solutions or gels which are unstable or have a limited lifespan.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée qui permet d'atténuer ou de supprimer les défauts organoleptiques de certaines préparations destinées à la voie orale. Another object of the present invention is to provide a form of extemporaneous administration which makes it possible to attenuate or eliminate the organoleptic defects of certain preparations intended for the oral route.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée à viscosité contrôlée destinée à remplacer les préparations liquides, visqueuses ou pâteuses habituellement utilisées par voie interne: sirops, solutions, dispersions, gels, formes effervescentes ou à diluer dans l'eau. Another object of the present invention is to provide a form of extemporaneous administration with controlled viscosity intended to replace the liquid, viscous or pasty preparations usually used internally: syrups, solutions, dispersions, gels, effervescent forms or to be diluted in water. 'water.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée à viscosité contrôlée pouvant être utilisée dans le traitement de la bouche sèche, des hyposialies ou des asialies. Another object of the present invention is to provide a form of extemporaneous administration with controlled viscosity which can be used in the treatment of dry mouth, hyposialias or asialias.
Un autre objet de la présente invention est de proposer une forme d'administration extemporanée à viscosité contrôlée destinée à remplacer les préparations liquides, visqueuses ou pâteuses habituellement utilisées par voie externe: gels, lotions, laits, crèmes, pommades... Another object of the present invention is to provide a form of extemporaneous administration with controlled viscosity intended to replace the liquid, viscous or pasty preparations usually used externally: gels, lotions, milks, creams, ointments ...
A cet effet, l'invention concerne une forme galénique solide, à usage interne ou externe, qui produit, dans un volume prédéterminé de solvant aqueux ou hydroalcoolique, une solution ou dispersion extemporanée à viscosité contrôlée et sans mousse, caractérisée en ce qu'elle comprend, outre le ou les principes actifs ou éléments nutritifs, un composé apte à former dans ce solvant aqueux un gel hydrocolloïde et un composé ou mélange de composés apte à former dans le même solvant des bulles destinées à y disperser le composé gélifiant et les composants du mélange, et à homogénéiser la solution ou dispersion, en la maintenant sous agitation, le temps que le gel se forme. To this end, the invention relates to a solid dosage form, for internal or external use, which produces, in a predetermined volume of aqueous or hydroalcoholic solvent, an extemporaneous solution or dispersion with controlled viscosity and without foam, characterized in that it comprises, in addition to the active principle or nutrients, a compound capable of forming in this aqueous solvent a hydrocolloid gel and a compound or mixture of compounds capable of forming in the same solvent bubbles intended to disperse the gelling compound and the components therein of the mixture, and to homogenize the solution or dispersion, keeping it under stirring, until the gel forms.
Le composé ou le mélange de composés apte à former des bulles, appelé communément mélange effervescent par l'homme de l'art, est constitué d'un acide physiologiquement acceptable et d'un carbonate ou bicarbonate de métal alcalin ou alcalino-terreux ou équivalent. En présence d'eau ce mélange réagit pour former un sel du métal alcalin ou alcalino-terreux et du gaz carbonique qui s'échappe du mélange sous forme de bulles. The compound or mixture of compounds capable of forming bubbles, commonly called effervescent mixture by those skilled in the art, consists of a physiologically acceptable acid and a carbonate or bicarbonate of an alkali or alkaline earth metal or equivalent . In the presence of water, this mixture reacts to form a salt of the alkali or alkaline earth metal and carbon dioxide which escapes from the mixture in the form of bubbles.
Le composé acide est choisi dans le groupe des acides, des anhydrides d'acide ou des sels d'acide: plus particulièrement dans le groupe constitué par l'acide citrique, l'acide tartrique, l'acide ascorbique, l'acide fumarique, l'acide nicotinique, l'acide acétylsalicylique, l'acide malique, l'acide adipique, l'acide succinique, l'anhydride glutarique, l'anhydride citrique... The acid compound is chosen from the group of acids, acid anhydrides or acid salts: more particularly from the group consisting of citric acid, tartaric acid, ascorbic acid, fumaric acid, nicotinic acid, acetylsalicylic acid, malic acid, adipic acid, succinic acid, glutaric anhydride, citric anhydride ...
Le carbonate ou bicarbonate de métal alcalin ou alcalino-terreux ou équivalent est choisi dans le groupe constitué par le carbonate de calcium, le carbonate de magnésium, le bicarbonate de potassium, le bicarbonate monosodique, le bicarbonate disodique, le carbonate de lysine, le carbasalate calcique, le bicarbonate de lithium... The alkali or alkaline earth metal carbonate or bicarbonate or equivalent is chosen from the group consisting of calcium carbonate, magnesium carbonate, potassium bicarbonate, monosodium bicarbonate, disodium bicarbonate, lysine carbonate, carbasalate calcium, lithium bicarbonate ...
La forme galénique de la présente invention comprend entre 5% et 60% ou plus de composé ou mélange de composés apte à former des bulles. The dosage form of the present invention comprises between 5% and 60% or more of compound or mixture of compounds capable of forming bubbles.
Le composé gélifiant est choisi parmi les agents gélifiants et/ou liants et/ou épaississants qui sont utilisés pour la fabrication de gels à usage interne ou externe. The gelling compound is chosen from gelling agents and / or binders and / or thickeners which are used for the manufacture of gels for internal or external use.
Plus particulièrement le composé gélifiant sera choisi dans le groupe constitué par les dérivés cellulosiques qui présentent l'avantage de caractéristiques physico-chimiques constantes et donc de produire des gels à viscosité contrôlée et reproductibles en milieux aqueux ou hydroalcoolique: la carboxyméthylcellulose, la méthylcellulose, l'hydroxypropylméthylcellulose, l'hydroxypropylcellulose, la méthylhydroxyéthylcellulose, la méthylhydroxypropylcellulose, l'hydroxyéthylcellulose et autres éthers de la cellulose, ou équivalents... More particularly the gelling compound will be chosen from the group consisting of cellulose derivatives which have the advantage of constant physicochemical characteristics and therefore of producing gels with controlled viscosity and reproducible in aqueous or hydroalcoholic media: carboxymethylcellulose, methylcellulose, l hydroxypropylmethylcellulose, hydroxypropylcellulose, methylhydroxyethylcellulose, methylhydroxypropylcellulose, hydroxyethylcellulose and other cellulose ethers, or equivalent ...
La quantité de composé gélifiant, constituant la forme galénique, permet d'obtenir des solutions ou dispersions de viscosité comprise entre 10 et 10 000 mPa.s ou plus. The amount of gelling compound, constituting the dosage form, makes it possible to obtain solutions or dispersions of viscosity between 10 and 10 000 mPa.s or more.
La forme galénique de la présente invention comprend entre 0.1% et 30% ou plus de composé gélifiant par forme. The dosage form of the present invention comprises between 0.1% and 30% or more of gelling compound per form.
Les excipients, tels que les agents de charge, lubrifiants, liants, plastifiants, conservateurs, arômes et autres, seront choisis en fonction de la forme galénique et de la voie d'administration désirées: comprimés, granulés, poudres et autres formes solides pour un usage interne ou externe. The excipients, such as bulking agents, lubricants, binders, plasticizers, preservatives, flavors and others, will be chosen according to the dosage form and the desired route of administration: tablets, granules, powders and other solid forms for a internal or external use.
La technologie de l'invention repose sur l'utilisation de l'effervescence, jouant le rôle de mélangeur-homogénéisateur, et de dérivés cellulosiques de synthèse comme la carboxyméthylcellulose (ou autres produits à propriétés équivalentes), qu'on utilise généralement pour épaissir, mettre en suspension, stabiliser, gélifier ou modifier les caractéristiques d'écoulement des solutions ou des dispersions aqueuses ou hydroalcooliques. The technology of the invention is based on the use of effervescence, playing the role of mixer-homogenizer, and synthetic cellulose derivatives such as carboxymethylcellulose (or other products with equivalent properties), which are generally used to thicken, suspend, stabilize, gel or modify the flow characteristics of aqueous or hydroalcoholic solutions or dispersions.
Ainsi, par exemple, la carboxyméthylcellulose présente des propriétés de pseudoplasticité qui se caractérisent par une diminution de la résistance à l'écoulement lorsqu'on lui applique un taux croissant de cisaillement (les molécules à chaînes longues ont tendance à s'orienter dans le sens du flux). Thus, for example, carboxymethylcellulose exhibits pseudoplasticity properties which are characterized by a decrease in flow resistance when an increasing shear rate is applied to it (molecules with long chains tend to orient in the direction of the flow).
La carboxyméthylcellulose en solution présente par ailleurs des propriétés de thixotropie qui se caractérisent par une augmentation de la viscosité apparente lorsque la solution demeure au repos pendant un certain temps après cisaillement. Carboxymethylcellulose in solution also exhibits thixotropy properties which are characterized by an increase in the apparent viscosity when the solution remains at rest for a certain time after shearing.
Ces solutions thixotropiques sont recherchées pour les suspensions de solides ou de produits insolubles: les principes actifs et les composants denses ou insolubles sont ainsi maintenus dispersés au sein de la dispersion naissante avant leur administration et les produits solubles à défaut organoleptique sont maintenus isolées des papilles gustatives. These thixotropic solutions are sought for suspensions of solids or insoluble products: the active principles and the dense or insoluble components are thus kept dispersed within the nascent dispersion before their administration and the soluble products with organoleptic defect are kept isolated from the taste buds .
D'autre part les dérivés cellulosiques de synthèse sont compatibles avec la plupart des gommes hydrosolubles dans une large gamme de concentration: les mélanges de ce genre permettent d'obtenir des solutions sans mousse et de viscosité considérablement plus élevée. On the other hand, synthetic cellulose derivatives are compatible with most water-soluble gums in a wide range of concentrations: mixtures of this kind make it possible to obtain solutions without foam and of considerably higher viscosity.
Généralement ces agents gélifiants présentent l'inconvénient de nécessiter des mélange longs et énergiques afin d'éviter la formation de grumeaux et d'agrégats. L'effervescence devient alors le seul moyen simple, à la disposition de l'utilisateur final pour obtenir des gels homogènes. Generally these gelling agents have the disadvantage of requiring long and vigorous mixing in order to avoid the formation of lumps and aggregates. The effervescence then becomes the only simple means, available to the end user to obtain homogeneous gels.
L'invention cumule donc les avantages d'une forme solide (absence d'eau, précision du dosage, utilisation, conservation et conditionnement aisés) et d'une forme liquide extemporanée à viscosité contrôlée, intégrant d'origine le mélangeurhomogénéisateur permettant à l'agent gélifiant de se disperser rapidement et sans grumeaux, tout en maintenant l'homogénéisation du mélange par l'agitation le temps que le gel se forme. The invention therefore combines the advantages of a solid form (absence of water, easy dosing, easy use, conservation and packaging) and an extemporaneous liquid form with controlled viscosity, integrating the homogenizer mixer allowing the gelling agent to disperse quickly and without lumps, while maintaining the homogenization of the mixture by stirring while the gel forms.
L'invention sera maintenant illustrée, à titre non limitatif, par des exemples de formules comportant des dérivés de la cellulose. Mais il doit être compris que l'invention ne doit pas être restreinte à l'emploi de ces composés. Tout composé ayant la même fonction et le même résultat entre dans le cadre de l'invention. The invention will now be illustrated, without implied limitation, by examples of formulas comprising derivatives of cellulose. However, it should be understood that the invention should not be restricted to the use of these compounds. Any compound having the same function and the same result is within the scope of the invention.
EXEMPLE 1: Comprimé effervescent à défaut organoleptique. EXAMPLE 1 Effervescent tablet with organoleptic defect.
Comprimé de Paracétamol. Paracetamol tablet.
Paracétamol: 500 mg
Acide Citrique anhydre: 1250 mg
Bicarbonate de Sodium: 1500 mg
Carboxyméthylcellulose CRT 30 000 PA: 300 mg
Polyvinylpyrrolidone: 10 mg
Stéarate de Magnésium: 1 mg
Saccharinate de Sodium: 15 mg
Arôme orange: 10 mg
Soit pour un comprimé de 3586 mg
Après la dissolution complète du comprimé, dans un verre d'eau, on obtient une solution limpide et légèrement sirupeuse. Les sensations amères et salées sont beaucoup moins prononcées par rapport à la solution d'un comprimé de même composition mais sans carboxyméthylcellulose. Paracetamol: 500 mg
Citric acid anhydrous: 1250 mg
Sodium bicarbonate: 1500 mg
Carboxymethylcellulose CRT 30,000 PA: 300 mg
Polyvinylpyrrolidone: 10 mg
Magnesium stearate: 1 mg
Sodium Saccharinate: 15 mg
Orange flavor: 10 mg
Either for a 3586 mg tablet
After the complete dissolution of the tablet, in a glass of water, a clear and slightly syrupy solution is obtained. The bitter and salty sensations are much less pronounced compared to the solution of a tablet of the same composition but without carboxymethylcellulose.
EXEMPLE 2: Gel pour le traitement des hyposialies et asialies. EXAMPLE 2 Gel for the treatment of hyposialias and asialias.
Granulé de carboxyméthylcellulose. Carboxymethylcellulose granule.
Acide Citrique anhydre: 1250 mg
Bicarbonate de Sodium: 1500 mg
Carboxyméthylcellulose CRT 30 000 PA: 400 mg
Polyvinylpyrrolidone: 10 mg
Stéarate de Magnésium: 1 mg
Saccharinate de Sodium: 15 mg
Arôme orange: 10 mg
Soit pour sachet dose de 3186 mg
Après la dissolution du granulé, dans un gobelet doseur de 40 ml d'eau, on obtient un gel transparent qui aidera à la déglutition d'un patient hyposialique ou asialique. La viscosité de ce gel avoisine 3 000 mPa.s (Viscosité à 25 "C, BrookEleld
LVT).Citric acid anhydrous: 1250 mg
Sodium bicarbonate: 1500 mg
Carboxymethylcellulose CRT 30,000 PA: 400 mg
Polyvinylpyrrolidone: 10 mg
Magnesium stearate: 1 mg
Sodium Saccharinate: 15 mg
Orange flavor: 10 mg
Either for a 3186 mg dose sachet
After dissolving the granule, in a measuring cup of 40 ml of water, a transparent gel is obtained which will help swallowing a hyposialic or asialic patient. The viscosity of this gel is around 3000 mPa.s (Viscosity at 25 "C, BrookEleld
LVT).
EXEMPLE 3: Gel pour le traitement de la toux productive. EXAMPLE 3 Gel for the treatment of productive cough.
Granulé de N-Acétylcystéine. N-Acetylcysteine granule.
N-Acétylcystéine: 200 mg
Acide Citrique anhydre: 1250 mg
Bicarbonate de Sodium: 1500 mg
Carboxyméthylcellulose CRT 30 000 PA: 500 mg
Polyvinylpyrrolidone: 10 mg
Stéarate de Magnésium: 1 mg
Saccharinate de Sodium: 15 mg
Arôme orange: 10 mg
Soit pour un sachet dose de 3486 mg
Après la dissolution du granulé, dans un verre d'eau, on obtient une solution sirupeuse, transparente et lubrifiante qui peut aider à traiter les troubles de l'expectoration. La viscosité de ce gel avoisine 1 500 mPa.s (Viscosité à 25 "C, BrookEleld LVT). N-Acetylcysteine: 200 mg
Citric acid anhydrous: 1250 mg
Sodium bicarbonate: 1500 mg
Carboxymethylcellulose CRT 30,000 PA: 500 mg
Polyvinylpyrrolidone: 10 mg
Magnesium stearate: 1 mg
Sodium Saccharinate: 15 mg
Orange flavor: 10 mg
Either for a 3486 mg dose sachet
After dissolving the granule in a glass of water, a syrupy, transparent and lubricating solution is obtained which can help treat sputum disorders. The viscosity of this gel is around 1,500 mPa.s (Viscosity at 25 "C, BrookEleld LVT).
EXEMPLE 4: Gel pour le traitement des affections buccodentaires. EXAMPLE 4 Gel for the treatment of oral diseases.
Granulé de Digluconate de Chlorhexidine. Granulated with Chlorhexidine Digluconate.
Digluconate de Chlorhexidine: 120 mg
Acide Citrique anhydre: 625 mg
Bicarbonate de Sodium: 750 mg
Méthylcellulose: 300 mg
Polyvinylpyrrolidone: 5 mg
Stéarate de Magnésium: 0,5 mg
Saccharinate de Sodium: 6 mg
Arôme Menthe-Eucalyptol 5 mg
Soit pour un flacon doseur 1811,5 mg
Après la dissolution du granulé dans un flacon doseur de 60 ml (20 ml d'alcool éthylique à 96" et 40 ml d'eau), on obtient une solution visqueuse, transparente et stable pendant 48 heures, qui aidera au traitement des affections buccodentaires: plaque dentaire, gingivite, stomatites... . La viscosité de ce gel avoisine 1 000 mPa.s (Viscosité à 25 "C, Brookfield LVT).Chlorhexidine digluconate: 120 mg
Citric acid anhydrous: 625 mg
Sodium bicarbonate: 750 mg
Methylcellulose: 300 mg
Polyvinylpyrrolidone: 5 mg
Magnesium stearate: 0.5 mg
Sodium Saccharinate: 6 mg
Mint-Eucalyptol flavor 5 mg
Either for a dosing bottle 1811.5 mg
After dissolving the granule in a 60 ml dosing bottle (20 ml of 96 "ethyl alcohol and 40 ml of water), a viscous, transparent and stable solution is obtained for 48 hours, which will help in the treatment of oral diseases : dental plaque, gingivitis, stomatitis ... The viscosity of this gel is around 1000 mPa.s (Viscosity at 25 "C, Brookfield LVT).
EXEMPLE 5: Gel antiseptique en dermatologie. EXAMPLE 5 Antiseptic gel in dermatology.
Granulé de Hexamidine Diisétionate. Granule of Hexamidine Diisionionate.
Hexamidine Diisétionate: 100 mg
Acide Citrique anhydre: 1250 mg
Bicarbonate de Sodium: 1500 mg
Carboxyméthylcellulose CRT 30 000 PA: 600 mg
Polyvinylpyrrolidone: 10 mg
Stéarate de Magnésium: 1 mg
Soit pour un sachet dose de 3661 mg
Après la dissolution du granulé dans 100 ml d'eau bouillie on obtient une solution visqueuse, transparente et stable pendant 48 heures, qui aidera au traitement d'appoint des affections en dermatologie, stomatologie, gynécologie... La viscosité de ce gel avoisine 1 900 mPa.s (Viscosité à 25 "C, Brookfield LVT). Hexamidine Diisionionate: 100 mg
Citric acid anhydrous: 1250 mg
Sodium bicarbonate: 1500 mg
Carboxymethylcellulose CRT 30,000 PA: 600 mg
Polyvinylpyrrolidone: 10 mg
Magnesium stearate: 1 mg
Either for a 3661 mg sachet dose
After dissolving the granule in 100 ml of boiled water, a viscous, transparent and stable solution is obtained for 48 hours, which will help in the adjunctive treatment of affections in dermatology, stomatology, gynecology ... The viscosity of this gel is around 1 900 mPa.s (Viscosity at 25 "C, Brookfield LVT).
Claims (20)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9611061A FR2753097A1 (en) | 1996-09-11 | 1996-09-11 | Solid dosage form giving controlled viscosity solution or dispersion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9611061A FR2753097A1 (en) | 1996-09-11 | 1996-09-11 | Solid dosage form giving controlled viscosity solution or dispersion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR2753097A1 true FR2753097A1 (en) | 1998-03-13 |
Family
ID=9495634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9611061A Withdrawn FR2753097A1 (en) | 1996-09-11 | 1996-09-11 | Solid dosage form giving controlled viscosity solution or dispersion |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2753097A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10019313A1 (en) * | 2000-04-19 | 2001-11-08 | Wella Ag | Use of gasified particles of popping candy type for cosmetic treatment, especially of hair, and cosmetic agents and instant gels containing the particles |
| WO2002005753A1 (en) * | 2000-07-17 | 2002-01-24 | Corneal Industrie | Polymer hydrogel resistant to biodegradation, preparation and use thereof as tissue regeneration support |
| EP1059076A3 (en) * | 1999-06-09 | 2003-04-16 | Wella Aktiengesellschaft | Preparation of an instant gel and the use of gaseous solid particles for cosmetic treatments |
| EP1104288A4 (en) * | 1998-08-12 | 2003-04-16 | Cima Labs Inc | Orally disintegrable tablet forming a viscous slurry |
| EP1426043A1 (en) * | 2002-11-07 | 2004-06-09 | B.S.D. | Effervescent pharmaceutical compositions for non conventional suspensions |
| EP1688131A1 (en) * | 1998-08-12 | 2006-08-09 | Cima Labs Inc. | Orally disintegratable tablet forming a viscous slurry |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2174004A (en) * | 1985-04-23 | 1986-10-29 | American Cyanamid Co | Effervescent tablets |
| EP0228164A2 (en) * | 1985-11-15 | 1987-07-08 | The Boots Company PLC | Effervescent composition containing ibuprofen |
| EP0396335A1 (en) * | 1989-04-28 | 1990-11-07 | Beecham Group p.l.c. | Pharmaceutical formulation |
| EP0415326A1 (en) * | 1989-08-31 | 1991-03-06 | Ss Pharmaceutical Co., Ltd. | Composition for foaming preparation |
| EP0467776A1 (en) * | 1990-07-16 | 1992-01-22 | Jacques Dubois | Pharmaceutical forms, their process of preparation and their uses |
| WO1992000731A1 (en) * | 1990-07-11 | 1992-01-23 | Eurand International Spa | Pharmaceutical composition for rapid suspension in water |
| WO1995014462A1 (en) * | 1993-11-26 | 1995-06-01 | Laboratoires Upsa | Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide |
| FR2715849A1 (en) * | 1994-02-09 | 1995-08-11 | Hesnard Xavier | Solid dosage compsn. contg. acid and carbonate |
| WO1996029993A1 (en) * | 1995-03-29 | 1996-10-03 | Mc2 | Solid delivery form for oral use |
-
1996
- 1996-09-11 FR FR9611061A patent/FR2753097A1/en not_active Withdrawn
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2174004A (en) * | 1985-04-23 | 1986-10-29 | American Cyanamid Co | Effervescent tablets |
| EP0228164A2 (en) * | 1985-11-15 | 1987-07-08 | The Boots Company PLC | Effervescent composition containing ibuprofen |
| EP0396335A1 (en) * | 1989-04-28 | 1990-11-07 | Beecham Group p.l.c. | Pharmaceutical formulation |
| EP0415326A1 (en) * | 1989-08-31 | 1991-03-06 | Ss Pharmaceutical Co., Ltd. | Composition for foaming preparation |
| WO1992000731A1 (en) * | 1990-07-11 | 1992-01-23 | Eurand International Spa | Pharmaceutical composition for rapid suspension in water |
| EP0467776A1 (en) * | 1990-07-16 | 1992-01-22 | Jacques Dubois | Pharmaceutical forms, their process of preparation and their uses |
| WO1995014462A1 (en) * | 1993-11-26 | 1995-06-01 | Laboratoires Upsa | Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide |
| FR2715849A1 (en) * | 1994-02-09 | 1995-08-11 | Hesnard Xavier | Solid dosage compsn. contg. acid and carbonate |
| WO1996029993A1 (en) * | 1995-03-29 | 1996-10-03 | Mc2 | Solid delivery form for oral use |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1104288A4 (en) * | 1998-08-12 | 2003-04-16 | Cima Labs Inc | Orally disintegrable tablet forming a viscous slurry |
| EP1688131A1 (en) * | 1998-08-12 | 2006-08-09 | Cima Labs Inc. | Orally disintegratable tablet forming a viscous slurry |
| EP1059076A3 (en) * | 1999-06-09 | 2003-04-16 | Wella Aktiengesellschaft | Preparation of an instant gel and the use of gaseous solid particles for cosmetic treatments |
| EP1616555A2 (en) | 1999-06-09 | 2006-01-18 | Wella Aktiengesellschaft | Preparation of an instant gel and the use of gaseous solid particles as acoustic indicator |
| EP1616555A3 (en) * | 1999-06-09 | 2006-06-21 | Wella Aktiengesellschaft | Preparation of an instant gel and the use of gaseous solid particles as acoustic indicator |
| DE10019313A1 (en) * | 2000-04-19 | 2001-11-08 | Wella Ag | Use of gasified particles of popping candy type for cosmetic treatment, especially of hair, and cosmetic agents and instant gels containing the particles |
| DE10019313B4 (en) * | 2000-04-19 | 2004-09-30 | Wella Ag | Instant gel with acoustic indicator, agents containing it, process for its production, and the use of gasified particles as an acoustic indicator |
| WO2002005753A1 (en) * | 2000-07-17 | 2002-01-24 | Corneal Industrie | Polymer hydrogel resistant to biodegradation, preparation and use thereof as tissue regeneration support |
| EP1426043A1 (en) * | 2002-11-07 | 2004-06-09 | B.S.D. | Effervescent pharmaceutical compositions for non conventional suspensions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0233853B1 (en) | Effervescent couples, effervescent compositions of h2-antagonists of histamine and their preparation | |
| CA1091579A (en) | Pharmaceutical compositions containing baryum as x- ray contrast media and preparation process therefrom | |
| BE1005691A4 (en) | Pharmaceutical composition containing ranitidine and method of preparation. | |
| EP0399902B1 (en) | Porous pharmaceutical form and process to prepare it | |
| BE1015217A5 (en) | ||
| JPS62123133A (en) | Preparation of dry carrier for controlled long life blended medicine and dry carrier thereby | |
| CA2150945C (en) | Ibuprofen-containing effervescent pharmaceutical composition and process for preparing the same | |
| TWI526205B (en) | Novel pharmaceutical formulation | |
| FR2484834A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING IBUPROFEN ALUMINUM SALTS | |
| FR2495471A1 (en) | COMPOSITIONS FOR THE TREATMENT OF ACNE | |
| BE1000168A3 (en) | Pharmaceutical composition containing soluble n-acetyl-cysteine and sorbitol. | |
| JP2015522030A (en) | Racecadotril liquid composition | |
| CA2452239C (en) | Pharmaceutical formulation having a masked taste and method for the production thereof | |
| FR2753097A1 (en) | Solid dosage form giving controlled viscosity solution or dispersion | |
| FR2661610A1 (en) | Novel lyophilised form of diosmin and its preparation | |
| WO2003061691A1 (en) | Orodispersible pharmaceutical composition comprising perindopril | |
| EP0983065A1 (en) | Gastric-retained pharmaceutical composition | |
| LU83363A1 (en) | ANTI-TUMOR COMPOSITIONS | |
| EP0830144B1 (en) | Water soluble, powder form compositions and applications thereof | |
| CA2532608A1 (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
| BE1007926A3 (en) | Pharmaceutical composition containing n-acetyl-cysteine. | |
| FR2987559A1 (en) | Composition in form of dispersible paste/aqueous suspension to treat anemia resulting from martial deficiency, comprises ferrous succinate and succinic acid that are dispersed in mixture including polyol, suspending and sweetening agents | |
| WO2003061650A1 (en) | Orodispersible pharmaceutical composition comprising mitiglinide | |
| FR2741532A1 (en) | NOVEL PHARMACEUTICAL COMPOSITIONS WITH ANTIMIGRAINE ACTION AND THEIR PREPARATION METHOD | |
| JPS5942318A (en) | Therapeutical composition, manufacture and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |